Zoetis Inc Class A ZOTS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Zoetis Up Over 8%, on Pace for Largest Percent Increase Since April 2020 — Data Talk
-
Zoetis Raises Guidance After 2Q Sales, Earnings Rise
-
Zoetis to Sell Medicated-Feed-Additive Portfolio to Phibro for $350 Million
-
Zoetis's stock falls 8% after report that its arthritis shots may have sickened pets
-
Zoetis Down Over 7%, on Pace for Largest Percent Decrease Since November 2022 — Data Talk
-
Zoetis Shares Slip Premarket After WSJ Report on Arthritis Drugs for Pets
-
Zoetis to Be Investigated by EU Over Possible Breach of Competition Rules — 2nd Update
-
EU to Investigate Zoetis Over Possible Breach of Competition Rules — Update
Trading Information
- Previous Close Price
- €172.68
- Day Range
- €172.34–173.52
- 52-Week Range
- €137.08–184.75
- Bid/Ask
- €173.20 / €174.02
- Market Cap
- €78.61 Bil
- Volume/Avg
- 0 / 7
Key Statistics
- Price/Earnings (Normalized)
- 33.89
- Price/Sales
- 9.67
- Dividend Yield (Trailing)
- 0.88%
- Dividend Yield (Forward)
- 0.90%
- Total Yield
- 2.46%
Company Profile
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Large Core
- Total Number of Employees
- 14,100
- Website
- https://www.zoetis.com
Competitors
Valuation
|
Metric
|
ZOTS
|
MRK
|
LLY
|
|---|---|---|---|
Price/Earnings (Normalized) | 33.89 | 17.37 | 81.48 |
Price/Book Value | 17.00 | 6.58 | 60.37 |
Price/Sales | 9.67 | 4.61 | 21.11 |
Price/Cash Flow | 29.47 | 15.37 | 81.86 |
Price/Earnings
ZOTS
MRK
LLY
Financial Strength
|
Metric
|
ZOTS
|
MRK
|
LLY
|
|---|---|---|---|
Quick Ratio | 1.64 | 0.88 | 0.61 |
Current Ratio | 3.45 | 1.47 | 1.11 |
Interest Coverage | 12.68 | 13.07 | 15.08 |
Quick Ratio
ZOTS
MRK
LLY
Profitability
|
Metric
|
ZOTS
|
MRK
|
LLY
|
|---|---|---|---|
Return on Assets (Normalized) | 18.00% | 15.46% | 13.15% |
Return on Equity (Normalized) | 51.43% | 41.15% | 69.16% |
Return on Invested Capital (Normalized) | 22.69% | 22.92% | 23.97% |
Return on Assets
ZOTS
MRK
LLY
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Zoetis Inc Class A
ZTS
| Fpvbgfhcs | Tzpt | $88.3 Bil | |||
| Merck KGaA ADR
MKKGY
| Qhzsltwfvr | Kvhblv | $77.4 Bil | |||
| Haleon PLC ADR
HLN
| Mbdmsyfw | Sjdr | $47.3 Bil | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| Cdsbpqpl | Bpfx | $19.0 Bil | |||
| Viatris Inc
VTRS
| Xcnsqthlb | Trgj | $13.9 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Ykkqvmng | Xth | $13.4 Bil | |||
| Catalent Inc
CTLT
| Yxdknlb | Qvhwz | $10.9 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Fsxxqrzd | Znrvzh | $3.5 Bil | |||
| Perrigo Co PLC
PRGO
| Pdwbpfzdq | Bgx | $3.5 Bil | |||
| Green Thumb Industries Inc
GTBIF
| Zqztzvbgm | Hjqdz | $2.5 Bil |
United States